T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| 1 | +$3B | |
| 2 | +$1.34B | |
| 3 | +$1.26B | |
| 4 |
NVIDIA
NVDA
|
+$1.09B |
| 5 |
Broadcom
AVGO
|
+$1.05B |
Top Sells
| 1 | +$1.18B | |
| 2 | +$1.13B | |
| 3 | +$1.06B | |
| 4 |
Microsoft
MSFT
|
+$1.05B |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$961M |
Sector Composition
| 1 | Technology | 27.68% |
| 2 | Healthcare | 19.29% |
| 3 | Consumer Discretionary | 13.58% |
| 4 | Financials | 10.5% |
| 5 | Industrials | 9.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
PepsiCo
PEP
$200B
| $2.69M | ﹤0.01% |
19,144
-1,100,758
|
|
||
602
Crinetics Pharmaceuticals
CRNX
$4.56B
| $2.52M | ﹤0.01% |
60,584
-655,588
|
|
||
603
Duke Energy
DUK
$92.1B
| $2.5M | ﹤0.01% |
20,164
-399,538
|
|
||
604
FirstEnergy
FE
$26.3B
| $2.49M | ﹤0.01% |
54,364
+31,564
|
|
||
605
Jasper Therapeutics
JSPR
$50.7M
| $2.45M | ﹤0.01% |
1,028,806
+325,158
|
|
||
606
Exelon
EXC
$44.4B
| $2.43M | ﹤0.01% |
54,035
-1,995,833
|
|
||
607
L3Harris
LHX
$53B
| $2.36M | ﹤0.01% |
7,740
-149,976
|
|
||
608
CAVA Group
CAVA
$6.38B
| $2.29M | ﹤0.01% |
37,935
+22,451
|
|
||
609
Middleby
MIDD
$6.32B
| $2.2M | ﹤0.01% |
16,577
+14,379
|
|
||
610
Steris
STE
$25.5B
| $2.2M | ﹤0.01% |
8,877
+2,369
|
|
||
611
Cintas
CTAS
$73.9B
| $2.16M | ﹤0.01% |
10,500
+5,400
|
|
||
612
Crown Castle
CCI
$38.6B
| $2.06M | ﹤0.01% |
21,400
+10,400
|
|
||
613
Corcept Therapeutics
CORT
$8.94B
| $2.03M | ﹤0.01% |
24,439
-541,830
|
|
||
614
Mondelez International
MDLZ
$72B
| $1.98M | ﹤0.01% |
31,740
+12,925
|
|
||
615
Church & Dwight Co
CHD
$20.1B
| $1.94M | ﹤0.01% |
22,120
+11,120
|
|
||
616
Exxon Mobil
XOM
$495B
| $1.88M | ﹤0.01% |
16,700
+47
|
|
||
617
Southern Company
SO
$96.5B
| $1.85M | ﹤0.01% |
19,552
+11,927
|
|
||
618
Rollins
ROL
$29.1B
| $1.83M | ﹤0.01% |
31,239
+17,819
|
|
||
619
SiTime
SITM
$9.52B
| $1.83M | ﹤0.01% |
+6,089
|
|
||
620
Stifel
SF
$12.7B
| $1.78M | ﹤0.01% |
15,711
-168,375
|
|
||
621
Lamb Weston
LW
$8.33B
| $1.75M | ﹤0.01% |
+30,146
|
|
||
622
Walmart
WMT
$908B
| $1.67M | ﹤0.01% |
+16,200
|
|
||
623
Soleno Therapeutics
SLNO
$2.83B
| $1.67M | ﹤0.01% |
+24,675
|
|
||
624
Colgate-Palmolive
CL
$62.8B
| $1.65M | ﹤0.01% |
20,652
+7,636
|
|
||
625
Bank of America
BAC
$398B
| $1.6M | ﹤0.01% |
31,069
-2,035
|
|